Olema Pharmaceuticals Inc (NASDAQ: OLMA) shares are up 2.77%, or $0.06 per share, as on 12:03:57 est today. After Opening the Day at $2.20, 161,752 shares of Olema have exchanged hands and the stock has traded between $2.37 and $2.17.  

This year the company has a YTD change of 76.82%.

Olema expects its next earnings on 2022-08-10.

For technical charts, analysis, and more on Olema visit the company profile.

About Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist, and a selective ER degrader (SERD). OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase4 (CDK4)/6 demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.

To get more information on Olema Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Olema Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast

Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement

Target Hits 52-Week Low After Missing Badly on First Quarter Earnings

DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter

Another Crypto Winter Wipes Out Billions in Market Value

Inflation + Recession = Recipe for Volatility

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold

The Best Laid Plans of Mice and Men — Part I